Remarkably, the patient’s headache was relieved within three days after the initiation of CD5-IL15/IL15sushi CAR T cell therapy, displaying the CAR’s ability to cause rapid and profound improvements in the symptoms of CNS lymphoma. Here, CD5 is linked to primary central nervous system lymphoma.